Abstract 87P
Background
Glioblastoma is the most common and aggressive primary brain cancer with an overall survival of 15 months despite aggressive cytotoxic treatments. Therefore, identifying new therapeutic targets within the tumor microenvironment (TME) is critical for improving patient outcomes. In glioblastoma, macrophages make up to 30% of the bulk tumor, which include both yolk-sac derived tissue-resident microglia and monocyte-derived macrophages (MDMs) that are recruited from the bone marrow during inflammation. During hematopoiesis, MDMs can arise from granulocyte-monocyte progenitors (GMPs) or monocyte-dendritic cell progenitors (MDPs), which give rise to neutrophil-like or dendritic cell-like lineages, respectively. Although MDMs as a whole are often considered tumor-promoting, the functional role of specific MDM ontogenies is not known. Our recent study identified a subset of MPO+ MDMs associated with better overall survival, enhanced cytotoxic function, and gene expression suggestive of a GMP origin. Therefore, the aim of this study is to characterize the role of MDM ontogeny in brain tumor progression.
Methods
Using a combination of RNA-sequencing, in vitro functional assays and in vivo fate-mapping tools, we assessed the functional role of macrophage ontogeny in glioblastoma models. Additionally, we adoptively transferred monocytes cultured ex vivo from distinct developmental origins to trace their recruitment to tumors and assess the subsequent impact on tumor growth.
Results
Interestingly, macrophage ontogeny was associated with differences in MHC I-mediated and MHC II-mediated antigen presentation as well as unique profile of cytokines and chemokines, including MPO. Additionally, we found differences in phagocytosis towards glioma cells and upregulation of different inflammatory pathways. Importantly, adoptive transfer of monocytes of distinct ontogenies had opposing effects on brain tumor progression and resulted in significant changes to the TME and peripheral immune system.
Conclusions
Our findings shed light on the developmental origins of brain tumor MDMs and their putative regulatory impact in the TME.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Brain Tumour Foundation of Canada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract